Advertisement

Management Strategy in 249 Consecutive Patients With Obstructive Hypertrophic Cardiomyopathy Referred to a Dedicated Program

      The likelihood of success of conservative management of obstructive hypertrophic cardiomyopathy (HC) and the predictors of failure of conservative therapy are not known. We therefore evaluated the efficacy of an algorithm for the management of symptoms and predictors of failed conservative therapy in 249 consecutive symptomatic patients with obstructive HC referred to a dedicated HC program for management in general or for septal reduction therapy (SRT) in particular. There was considerable practice variation in the extent to which conservative therapy was optimized before referral for SRT. Over 3.7 ± 2.9-year follow-up, symptoms resolved with addition of or increase in dosage of a β blocker, calcium channel blocker, or disopyramide in 16%, 10%, and 10% of patients, respectively. Pacing with short atrioventricular delay controlled symptoms in 4 of 9 patients. In 63% of patients, conservative measures failed to control symptoms. Multivariate predictors of failure of conservative therapy were presence of New York Heart Association class III or IV symptoms (hazard ratio 2.0, 95% confidence interval 1.4 to 2.9, p = 0.001) and greater septal wall thickness (hazard ratio 1.06, 95% confidence interval 1.02 to 1.10, p = 0.003) at presentation. At time of presentation, 93 patients (37%) were already on optimal therapy and were referred for SRT. Of the remaining 156 patients who did not require immediate SRT, 93 (60%) were free from a recommendation for SRT at the end of the follow-up period. In conclusion, in symptomatic patients with obstructive HC, conservative therapy is successful in >1/3 of referred patients at 3.7-year follow-up, obviating SRT in these patients. Clinicians in programs offering SRT should optimize conservative therapy before recommending SRT.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Maron M.S.
        • Olivotto I.
        • Zenovich A.G.
        • Link M.S.
        • Pandian N.G.
        • Kuvin J.T.
        • Nistri S.
        • Cecchi F.
        • Udelson J.E.
        • Maron B.J.
        Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction.
        Circulation. 2006; 114: 2232-2239
        • Gersh B.J.
        • Maron B.J.
        • Bonow R.O.
        • Dearani J.A.
        • Fifer M.A.
        • Link M.S.
        • Naidu S.S.
        • Nishimura R.A.
        • Ommen S.R.
        • Rakowski H.
        • Seidman C.E.
        • Towbin J.A.
        • Udelson J.E.
        • Yancy C.W.
        ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
        J Am Coll Cardiol. 2011; 2011: e212-e260
        • Shah J.S.
        • Esteban M.T.
        • Thaman R.
        • Sharma R.
        • Mist B.
        • Pantazis A.
        • Ward D.
        • Kohli S.K.
        • Page S.P.
        • Demetrescu C.
        • Sevdalis E.
        • Keren A.
        • Pellerin D.
        • McKenna W.J.
        • Elliott P.M.
        Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy.
        Heart. 2008; 94: 1288-1294
        • Fifer M.A.
        • Vlahakes G.J.
        Management of symptoms in hypertrophic cardiomyopathy.
        Circulation. 2008; 117: 429-439
        • Morrow A.G.
        • Reitz B.A.
        • Epstein S.E.
        • Henry W.L.
        • Conkle D.M.
        • Itscoitz S.B.
        • Redwood D.R.
        Operative treatment in hypertrophic subaortic stenosis.
        Circulation. 1975; 52: 88-102
        • Woo A.
        • Williams W.G.
        • Choi R.
        • Wigle E.D.
        • Rozenblyum E.
        • Fedwick K.
        • Siu S.
        • Ralph-Edwards A.
        • Rakowski H.
        Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy.
        Circulation. 2005; 111: 2033-2041
        • Nagueh S.F.
        • Groves B.M.
        • Schwartz L.
        • Smith K.M.
        • Wang A.
        • Bach R.G.
        • Nielsen C.
        • Leya F.
        • Buergler J.M.
        • Rowe S.K.
        • Woo A.
        • Maldonado Y.M.
        • Spencer III, W.H.
        Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy.
        J Am Coll Cardiol. 2011; 58: 2322-2328
        • Fifer M.A.
        • Sigwart U.
        Controversies in cardiovascular medicine.
        Eur Heart J. 2011; 32: 1059-1064
        • Schulte H.D.
        • Bircks W.H.
        • Loesse B.
        • Godehardt E.A.
        • Schwartzkopff B.
        Prognosis of patients with hypertrophic obstructive cardiomyopathy after transaortic myectomy.
        J Thorac Cardiovasc Surg. 1993; 106: 709-717
        • Wann L.S.
        • Curtis A.B.
        • January C.T.
        • Ellenbogen K.A.
        • Lowe J.E.
        • Estes III, N.A.M.
        • Page R.L.
        • Ezekowitz M.D.
        • Slotwiner D.J.
        • Jackman W.M.
        • Stevenson W.G.
        • Tracy C.M.
        • Jacobs A.K.
        • Writing Group M
        2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2011; 123: 104-123
        • Harrison D.C.
        • Braunwald E.
        • Glick G.
        • Mason D.T.
        • Chidsey C.A.
        • Ross J.
        Effects of beta adrenergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis.
        Circulation. 1964; 29: 84-98
        • Rosing D.R.
        • Condit J.R.
        • Maron B.J.
        • Kent K.M.
        • Leon M.B.
        • Bonow R.O.
        • Lipson L.C.
        • Epstein S.E.
        Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III.
        Am J Cardiol. 1981; 48: 545-553
        • Sherrid M.V.
        • Barac I.
        • McKenna W.J.
        • Elliott P.M.
        • Dickie S.
        • Chojnowska L.
        • Casey S.
        • Maron B.J.
        Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
        J Am Coll Cardiol. 2005; 45: 1251-1258
        • Ommen S.R.
        • Maron B.J.
        • Olivotto I.
        • Maron M.S.
        • Cecchi F.
        • Betocchi S.
        • Gersh B.J.
        • Ackerman M.J.
        • McCully R.B.
        • Dearani J.A.
        • Schaff H.V.
        • Danielson G.K.
        • Tajik A.J.
        • Nishimura R.A.
        Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy.
        J Am Coll Cardiol. 2005; 46: 470-476
        • Ball W.
        • Ivanov J.
        • Rakowski H.
        • Wigle E.D.
        • Linghorne M.
        • Ralph-Edwards A.
        • Williams W.G.
        • Schwartz L.
        • Guttman A.
        • Woo A.
        Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment.
        J Am Coll Cardiol. 2011; 58: 2313-2321
        • Nishimura R.A.
        • Trusty J.M.
        • Hayes D.L.
        • Ilstrup D.M.
        • Larson D.R.
        • Hayes S.N.
        • Allison T.G.
        • Tajik A.J.
        Dual-chamber pacing for hypertrophic cardiomyopathy: A randomized, double-blind, crossover trial.
        J Am Coll Cardiol. 1997; 29: 435-441
        • Epstein S.E.
        • Rosing D.R.
        Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy.
        Circulation. 1981; 64: 437-441
        • Pollick C.
        • Kimball B.
        • Henderson M.
        • Wigle E.D.
        Disopyramide in hypertrophic cardiomyopathy.
        Am J Cardiol. 1988; 62: 1248-1251
        • Pollick C.
        Disopyramide in hypertrophic cardiomyopathy.
        Am J Cardiol. 1988; 62: 1252-1255
        • McDonald K.
        • McWilliams E.
        • O'Keeffe B.
        • Maurer B.
        Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy.
        Eur Heart J. 1988; 9: 893-898
        • Kappenberger L.
        • Linde C.
        • Daubert C.
        • McKenna W.
        • Meisel E.
        • Sadoul N.
        • Chojnowska L.
        • Guize L.
        • Gras D.
        • Jeanrenaud X.
        • Rydén L.
        Pacing in hypertrophic obstructive cardiomyopathy.
        Eur Heart J. 1997; 18: 1249-1256
        • Maron B.J.
        • Nishimura R.A.
        • McKenna W.J.
        • Rakowski H.
        • Josephson M.E.
        • Kieval R.S.
        Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy.
        Circulation. 1999; 99: 2927-2933